Palbociclib Patent Expiration
Palbociclib is Used for treating HR-positive, HER2-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant. It was first introduced by Pfizer Inc
Palbociclib Patents
Given below is the list of patents protecting Palbociclib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Ibrance | US10723730 | Solid forms of a selective CDK4/6 inhibitor | Feb 08, 2034 | Pfizer |
| Ibrance | US11065250 | Solid dosage forms of palbociclib | Aug 19, 2036 | Pfizer |
| Ibrance | US6936612 | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones |
Jan 16, 2023
(Expired) | Pfizer |
| Ibrance | US7208489 | 2-(pyridin-2-ylamino)-pyrido [2,3-d]pyrimidin-7-ones |
Jan 16, 2023
(Expired) | Pfizer |
| Ibrance | US7456168 | 2-(pyridin-2-ylamino)-pyrido[2,3, d]pyrimidin-7-ones |
Jan 16, 2023
(Expired) | Pfizer |
| Ibrance | USRE47739 | 2-(pyridin-2-ylamino)-pyrido[2,3-D]pyrimidin-7-ones | Mar 05, 2027 | Pfizer |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Palbociclib Generics
Several generic applications have been filed for Palbociclib.
Given below is the list of companies who have filed for Palbociclib generic.
1. SYNTHON PHARMS INC
Synthon Pharmaceuticals Inc has filed for 3 different strengths of generic version for Palbociclib. Given below are the details of the strengths of this generic introduced by Synthon Pharms Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 75MG | tablet | Prescription | ORAL | AB | Jun 5, 2024 |
| 100MG | tablet | Prescription | ORAL | AB | Jun 5, 2024 |
| 125MG | tablet | Prescription | ORAL | AB | Jun 5, 2024 |